image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Plus500

February 2020

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • PLUS
  • Price:
  • 922p
Plus500’s shares surged above £9 after the CFD provider released a short but reassuring trading update saying it expects to report revenue and EBITDA of around US$354m and US$190m, respectively. This represents a massive improvement in H2 in which EBITDA was c. US$125m versus US$65m in H1. The latter was largely due to a poor Q1 when market volatility was low.Management “is pleased with this performance…which benefited from continued optimisation of marketing spend, enhancements to customer service and improvements in its proprietary technology platform.”Liberum estimates Q4 ‘19 achieved c. 57% EBITDA margins but the broker has only factored in a 49% margin for 2020 and just 2.5% organic g ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X